Q1 EPS Estimate for Akero Therapeutics Boosted by Analyst

Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) - Equities researchers at HC Wainwright lifted their Q1 2025 earnings per share estimates for shares of Akero Therapeutics in a report issued on Monday, March 3rd. HC Wainwright analyst E. Arce now expects that the company will earn ($0.96) per share for the quarter, up from their prior estimate of ($1.16). HC Wainwright has a "Buy" rating and a $75.00 price target on the stock. The consensus estimate for Akero Therapeutics' current full-year earnings is ($3.99) per share. HC Wainwright also issued estimates for Akero Therapeutics' Q2 2025 earnings at ($1.00) EPS, Q3 2025 earnings at ($1.04) EPS, Q4 2025 earnings at ($1.08) EPS, FY2025 earnings at ($4.07) EPS, FY2026 earnings at ($4.55) EPS, FY2027 earnings at ($4.19) EPS, FY2028 earnings at ($2.95) EPS and FY2029 earnings at $2.67 EPS.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last issued its quarterly earnings results on Friday, February 28th. The company reported ($0.99) EPS for the quarter, missing analysts' consensus estimates of ($0.98) by ($0.01).

Several other equities research analysts have also commented on AKRO. Morgan Stanley reissued an "overweight" rating on shares of Akero Therapeutics in a research note on Sunday, March 2nd. Canaccord Genuity Group increased their price objective on shares of Akero Therapeutics from $56.00 to $73.00 and gave the stock a "buy" rating in a research note on Tuesday, January 28th. UBS Group lifted their price objective on Akero Therapeutics from $42.00 to $109.00 and gave the company a "buy" rating in a research report on Friday, January 31st. Citigroup boosted their price objective on Akero Therapeutics from $65.00 to $80.00 and gave the company a "buy" rating in a research report on Tuesday, January 28th. Finally, Bank of America upgraded shares of Akero Therapeutics from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $35.00 to $63.00 in a research note on Thursday, January 30th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $76.29.

Remove Ads

Akero Therapeutics Trading Down 1.0 %

Shares of AKRO stock traded down $0.44 during trading hours on Thursday, reaching $41.68. The company's stock had a trading volume of 1,279,401 shares, compared to its average volume of 846,659. The stock has a market capitalization of $3.32 billion, a P/E ratio of -11.11 and a beta of -0.19. The firm's fifty day simple moving average is $40.49 and its 200 day simple moving average is $33.28. Akero Therapeutics has a one year low of $17.86 and a one year high of $58.40. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05.

Insider Activity at Akero Therapeutics

In other news, CFO William Richard White sold 2,817 shares of the company's stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $30.79, for a total transaction of $86,735.43. Following the sale, the chief financial officer now owns 38,335 shares of the company's stock, valued at approximately $1,180,334.65. This represents a 6.85 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Timothy Rolph sold 4,818 shares of the firm's stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $30.91, for a total value of $148,924.38. Following the completion of the sale, the insider now owns 178,337 shares in the company, valued at approximately $5,512,396.67. This represents a 2.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 237,492 shares of company stock valued at $11,357,578. 7.94% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Akero Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. GF Fund Management CO. LTD. purchased a new position in shares of Akero Therapeutics during the 4th quarter worth approximately $41,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Akero Therapeutics by 18.3% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 71,451 shares of the company's stock valued at $1,988,000 after purchasing an additional 11,035 shares in the last quarter. Woodline Partners LP raised its stake in shares of Akero Therapeutics by 29.9% in the 4th quarter. Woodline Partners LP now owns 379,967 shares of the company's stock valued at $10,571,000 after purchasing an additional 87,499 shares in the last quarter. Two Sigma Advisers LP increased its stake in Akero Therapeutics by 195.7% during the fourth quarter. Two Sigma Advisers LP now owns 41,100 shares of the company's stock valued at $1,143,000 after purchasing an additional 27,200 shares during the last quarter. Finally, Two Sigma Investments LP grew its holdings in shares of Akero Therapeutics by 43.3% during the fourth quarter. Two Sigma Investments LP now owns 127,320 shares of the company's stock valued at $3,542,000 after purchasing an additional 38,500 shares during the last quarter.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.